Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pinatuzumab, a CD22 monoclonal antibody, specifically targets the CD22 cell-surface antigen and is utilized in the synthesis of antibody-drug conjugates (ADCs) for researching a range of diseases, including non-Hodgkin lymphoma (NHL) [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Pinatuzumab, a CD22 monoclonal antibody, specifically targets the CD22 cell-surface antigen and is utilized in the synthesis of antibody-drug conjugates (ADCs) for researching a range of diseases, including non-Hodgkin lymphoma (NHL) [1] [2]. |
Molecular Weight | N/A |
CAS No. | 1639820-81-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pinatuzumab 1639820-81-7 inhibitor inhibit